Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women aged 18-45 who are within 3 months of delivering a healthy, term (37 to 40 weeks) singleton~* diagnosis of bipolar postpartum depression - depressed with peripartum onset~* have a 17-item Hamilton Rating Scale for Depression score of \>18~* have failed to respond to an adequate trial of the mood stabilizer~* are currently not on any psychotropic drug except a mood stabilizer (lithium, lamotrigine or quetiapine)~* are able to communicate (written and oral) in English and capable of giving consent~Exclusion Criteria:~* current major depressive episode of more than 6 months duration~* a current comorbid psychiatric disorder~* history of alcohol or substance abuse within the 12 months before screening~* concurrent psychotherapy~* high risk for suicide (actively suicidal or a score of = 3 on item #3 on HAM-D)~* current hepatic, renal, or cardiac disease, chronic pain, coagulation disorders, esophageal or gastro duodenal ulceration within the previous 30 days~* known immediate-type hypersensitivity to COX-2 inhibitors, sulfonamides, ibuprofen, or diclofenac~* breastfeeding mothers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Adjunct celecoxib in 6 week treatment
- Placebo (Type: PLACEBO_COMPARATOR): Adjunct placebo in 6 week treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).